NASDAQ: $EYPT
A Major Milestone in Retinal Disease Treatment
EyePoint Pharmaceuticals has officially announced the topline results from its LUCIA study, the second pivotal Phase 3 clinical trial evaluating the efficacy and safety of DURAVYU (vorolanib) for the treatment of wet age-related macular degeneration (wet AMD).
Understanding the LUCIA Trial Results
The LUCIA trial was designed to evaluate the non-inferiority of DURAVYU compared to aflibercept. The study successfully met its primary endpoint, demonstrating that a single injection of DURAVYU maintained visual acuity with a favorable safety profile.
Key Findings from the Study:
- Primary Endpoint Met: DURAVYU demonstrated non-inferiority to aflibercept in the mean change in best-corrected visual acuity (BCVA) at 36 weeks.
- Treatment Durability: The trial highlights the potential for DURAVYU to reduce the treatment burden for patients, offering a long-acting delivery system.
- Safety Profile: The reported adverse events were generally consistent with expectations for intravitreal injections, with no new safety signals identified.
What This Means for Patients
Wet AMD is a chronic, vision-threatening condition that typically requires frequent eye injections. By providing a sustained-delivery treatment option, DURAVYU could significantly improve the quality of life for patients by reducing the frequency of clinic visits and injections required to manage their condition effectively.
As EyePoint moves forward, these results represent a critical step toward a potential regulatory filing, bringing the medical community closer to a new standard of care for retinal diseases.
Source: Read More